Skip Navigation


European Heart Journal Advance Access originally published online on April 13, 2005
European Heart Journal 2005 26(13):1249-1251; doi:10.1093/eurheartj/ehi296
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/13/1249    most recent
ehi296v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sattar, N.
Right arrow Articles by Forouhi, N. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sattar, N.
Right arrow Articles by Forouhi, N. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Metabolic syndrome criteria: ready for clinical prime time or work in progress?

Naveed Sattar1,* and Nita G. Forouhi2

1Section of Vascular Biochemistry, Division of Cardiovascular and Medical Sciences, 4th Floor QEB, Glasgow Royal Infirmary, University of Glasgow, Glasgow G31 2ER, UK
2MRC Epidemiology Unit, Cambridge CB1 8RN, UK

* Corresponding author. Tel: +44 141 211 4312; fax: +44 141 553 2558. E-mail address: nsattar@clinmed.gla.ac.uk

This editorial refers to ‘Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial’{dagger} by C.A. Geluk et al., on page 1314

The first 10% of the full text of this article appears below.

Geluk et al.1 describe a subgroup analysis of the PREVEND trial in which they tested whether pravastatin reduced risk for major adverse cardiac events in micro-albuminuric patients with and without the metabolic syndrome defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III) criteria.2 Although pravastatin did not reduce incidence of adverse cardiac events in the total cohort,3 an impressive 60% relative risk reduction was noted in the subgroup with both micro-albuminuria and metabolic syndrome [hazard ratio (HR) 0.39, 95% confidence interval (CI) 0.17–0.89], whereas micro-albuminuric individuals without metabolic syndrome did not appear to benefit. The higher event rate in the former group concurs with other evidence indicating a more ‘malignant’ outcome when micro-albuminuria accompanies other risk factors (e.g. endothelial dysfunction4) than when it occurs in isolation. The investigators suggested . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial
Christiane A. Geluk, Folkert W. Asselbergs, Hans L. Hillege, Stephan J.L. Bakker, Paul E. de Jong, Felix Zijlstra, and Wiek H. van Gilst
EHJ 2005 26: 1314-1320. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
J. F. V. Martin
Alike the metabolic syndrome, hypertension is more than just increased blood pressure
Eur. Heart J., May 1, 2006; 27(9): 1123 - 1129.
[Full Text] [PDF]